viewSativa Group PLC

Sativa Group PLC - Food Standard Authority ("FSA") guidelines welcome

RNS Number : 1057D
Sativa Group PLC
14 February 2020


Press Release


14 February 2020




The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 



Sativa Group Plc


("Sativa" or "the Company" or "the Group")


Sativa Group welcomes new Food Standard Agency ("FSA") guidelines


Sativa Group notes the recent announcement by the Food Standards Agency ("FSA") concerning the safe use of CBD products and the timetable for Novel Food authorisation.  It welcomes the clarity of a regulatory framework as an important step leading to the development of a safe and legal market in the UK for CBD. 


Sativa's products, sold under the Goodbody Botanicals, Goodbody Wellness, Tessellate and GB brands, are THC free and are rigorously tested before despatch to ensure that they are free of solvents and other contaminants.  Product labelling and packaging clearly explains the recommended daily intake, which is in-line with FSA guidelines.  The QR code on each label links to the website giving the Certificate of Analysis of each specific batch. 


Sativa, as a founding member of the Association for the Cannabinoid Industry, is at the vanguard of setting industry standards and engaging with regulators, and is fully committed to the process of obtaining Novel Food regulatory approval for its products. 


Henry Lees-Buckley, Chief Executive Office of Sativa, said: "This guidance from the FSA will reassure our customers and distribution partners that Sativa is at the forefront of building a sustainable CBD wellness industry.  Sativa, incorporating its Phytovista Laboratory, Home Office licences for research with King's College London, and Scientific Advisory Board, continues to invest in the infrastructure to ensure we are fully compliant with industry regulation." 


-     Ends -



Media enquiries. 

Abchurch Communications

Julian Bosdet

+44 (0)207 4594 4070 

+44 (0) 7771 663 886 

[email protected]




For further information please contact: 


Henry Lees-Buckley 

Chief Executive Officer

Sativa Group Plc 

+44 (0) 20 7971 1255


[email protected]


Joseph Colliver

Chief Financial Officer

Sativa Group Plc 

+44 (0) 20 7971 1255


[email protected]o.uk 


NEX Exchange Corporate Adviser


Corporate Finance 

Stephen Keys / Max Gould 

Cenkos Securities plc 

+44 (0) 20 7397 8900



Equity Sales 

Julian Morse

Cenkos Securities

+44 (0) 20 7397 8900


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Sativa Group PLC

Price: 2.35

Market: AQSE
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Sativa Investments PLC acquires UK-based PhytoVista Laboratories

Geremy Thomas, chief executive of Sativa Investments PLC (AQSE:SATI), tells Proactive's Andrew Scott they've agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000. The British medicinal cannabis investment vehicle will pay £235,000...

on 4/7/18